Investigation of the biological mechanism of GLUT1 to develop it as a novel therapeutic predictive biomarker for realization of the personalized lung cancer medicine

• Project/Area Number: 23790928
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Shizuoka Cancer Center Research Institute
• Principal Investigator: SERIZAWA Masakuni 静岡県立静岡がんセンター(研究所), 研究員 (00569915)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
• Keywords: GLUT1 / PET / 治療効果予測マーカー / 肺癌 / mTOR阻害剤 / FDG / mTOR / 肺がん / 個別化医療 / 分子標的型抗がん剤 / グルコース

Research Abstract

We conducted a basic study in non-small cell lung cancer for the purpose of using positron emission tomography (PET) as a predictive marker for the effects of mTOR inhibitors. From the results, we were able to clarify the relationship between mTOR inhibitors and the accumulation of 2-[18F]-fluoro-2-deoxy-D-glucose used in PET as well as the potential of PTEN as a factor determining the sensitivity to mTOR inhibitors.

Research Products

• [Journal Article] Combined treatment with erlotinib and transforming growth factor-β type 1 receptor (TGF-βRI) inhibitor is effective to suppress the enhanced cell motility of erlotinib-resistant non-small cell lung cancer cells. (2013)
  • Author(s): Serizawa, M., Takahashi, T., Yamamoto, N., Koh, Y.
  • Journal Title: J Thorac Oncol. Volume: 8 Pages: 259-269
  • Peer Reviewed
• [Journal Article] The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who received concurrent chemoradiotherapy (2012)
  • Author(s): Akamatsu, H., Kaira, K., Murakami, H., Serizawa, M., Koh, Y., Ono, A., Shukuya, T., Tsuya, A., Nakamura, Y., Kenmotsu, H., Naito, T., Takahashi, T., Endo, M., Harada, H., Nakajima, T., Yamamoto, N.
  • Journal Title: Am J Clin Oncol.
  • Peer Reviewed
• [Journal Article] Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. (2012)
  • Author(s): Kaira, K., Serizawa, M., Koh, Y., Takahashi, T., Hanaoka, H., Oriuchi, N., Endo, M., Kondo, H., Nakajima, T., Yamamoto, N.
  • Journal Title: Eur J Cancer. Volume: 48 Pages: 1244-1254
  • Peer Reviewed
• [Journal Article] Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N. (2012)
  • Author(s): Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
  • Journal Title: European Journal of Cancer Volume: 48 Issue: 8 Pages: 1244-54
  • DOI: 10.1016/j.ejca.2012.01.016
  • Peer Reviewed
• [Journal Article] バイオバンクと個別化医療 (2011)
  • Author(s): 芹澤昌邦、洪 泰浩
  • Journal Title: Progress in Medicine 基礎・治療 Volume: 31 Pages: 2575-2580
• [Journal Article] Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. (2011)
  • Author(s): Kaira, K, Serizawa, M., Koh, Y., Miura, S., Kaira, R., Abe, M., Nakagawa, K., Ohde, Y., Okumura, T., Murakami, H., Tsuya, A., Nakamura, Y., Naito, T., Takahashi, T., Kondo, H., Nakajima, T., Endo, M., Yamamoto, N.
  • Journal Title: Lung Cancer. Volume: 74 Pages: 419-425
  • Peer Reviewed
• [Journal Article] Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors. (2011)
  • Author(s): Kaira, K., Serizawa M., Koh, Y., Miura, S., Kaira, R., Abe, M., Nakagawa, K., Ohde, Y., Okumura, T., Naito, T., Murakami, H., Takahashi, T., Kondo, H., Nakajima, T., Endo, M., Yamamoto, N.
  • Journal Title: J Thorac Oncol. Volume: 6 Pages: 606-613
  • Peer Reviewed
• [Journal Article] MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. (2011)
  • Author(s): Kaira, K., Murakam,I H., Serizawa, M., Koh, Y., Abe, M., Ohde, Y., Takahashi, T., Kondo, H., Nakajima, T., Yamamoto, N.
  • Journal Title: Virchows Arch. Volume: 458 Pages: 615-620
  • Peer Reviewed